BioPharmSignal logoBioPharmSignal

Biotech News

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT)Sight SciencesCompany update

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August

Related news

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

BLTEBelite Bio2026-08-11 20:01 EST

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

BLTEBelite Bio2026-09-08 10:00 EST

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

OCGNOcugen2026-07-29 11:01 EST

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

SGHTSight Sciences2026-08-19 11:05 EST

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

SGHTSight Sciences2026-08-05 20:04 EST

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Stock data

Close
9.03 USD
Market cap
236.14M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States